To date, several HDAC inhibitors (HDACi) like hydroxamic acids, benzamides, short chain carbolic acids, and cyclic tetrapeptides have been characterized in vitro and ex vivo for various cancers [33–36]. Here, HDAC9 is linked to cancer.